NEWAMSTERDAM PHARMA CO NVNAMS
ASignal's systematic analysis rates NAMS as Bearish.
Reflects the latest available analysis · analyzed Sep 5, 2026
The case on NAMS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong cash position with $633.85M in total cash
- Low debt-to-equity ratio (0.00x) indicating minimal leverage risk
- High current and quick ratios (9.03x, 8.76x) suggesting strong short-term liquidity
- Gross margin of 100.00% indicating full pricing control on products
- Severely negative operating margin (-1752.61%) signaling significant operational inefficiencies
- Negative return on equity (-36.81%) and return on assets (-20.11%)
- Negative free cash flow (-$45.36M) and operating cash flow (-$143.46M)
- Revenue growth declining YoY by 80.70%
- Forward P/E of -16.27x and negative EV/EBITDA (-9.84x) indicating unprofitability
- Extremely high price-to-sales ratio (416.99x) and EV/revenue (337.38x)
See the full verdict on NAMS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NAMS
Most investors never get a second opinion, let alone several. ASignal runs NAMS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.